Skip to main content

Advertisement

Table 2 The clinical manifestations of disease in each study group

From: A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients

Clinical symptoms and signs Treatment group
Number (%)
Control group
Number (%)
Blurred vision 3 (10) 8 (32)
Diplopia 6 (20) 4 (16)
Gait problem 4 (13.3) 2 (8)
Paresthesia 8 (26.6) 6 (24)
Muscle weakness 3 (10) 3 (12)
Dysarthria 0 (0) 6 (24)
Bladder dysfunction 1 (3.3) 1 (4)